1910 Genetics Appoints Dr Jennifer Leeds as Independent Director | Nation / World


BOSTON – (BUSINESS WIRE) – December 15, 2021–

1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, today announced that Jennifer Leeds, Ph.D., will join as a member independent from the board of directors of the company. With two decades in the pharmaceutical industry, Dr Leeds joins 1910 Genetics with extensive experience in drug discovery and development, including strategic partnerships and the evaluation of new targets, platforms and technologies.

This press release features multimedia. See the full version here: https://www.businesswire.com/news/home/20211215005296/en/

Jennifer Leeds, Ph.D. appointed to 1910 Genetics Board of Directors. (Photo: Business Wire)

“In this role on the board, we were looking for someone who is an experienced drug hunter with a demonstrated ability to successfully bring target discovery drugs to the clinic, and Jenn fits the bill, as shown. his experience in the infectious disease project and his strategic leadership in all drug classes. and modalities. She is also the rare therapeutic expert who brings her strong business development acumen, assisting the NIBR to research and evaluate active therapeutics in the western United States and Canada, ”said Jen Nwankwo, Ph.D., founder and CEO of 1910 Genetics. “This rare combo of drug hunter and business executive will be an invaluable addition to our team and help us recognize the full potential of our platforms in all areas of disease. As a founder, CEO and first-time entrepreneur, I am personally delighted to have Jenn as a mentor.

Prior to joining the 1910 Genetics Board of Directors, Dr Leeds held several leadership positions during his 19 years at NIBR. Currently, she is the Executive Director of Business Development and Licensing, leading early development discovery and research and evaluation efforts in the western United States and Canada, and supporting asset licensing. of NIBR’s global portfolio. She was also a member of the Novartis COVID-19 working group and played a critical role in the assessment and partnership around COVID-19 assets. In addition, Dr Leeds was Executive Director and Head of Antibacterial Discovery, Infectious Diseases at NIBR and was responsible for managing the global and interdivisional project teams, as well as the strategic growth of the Novartis Antibacterial Discovery group and portfolio. She is the author of over 40 peer-reviewed journal articles and is cited as an inventor in several patent applications.

Dr Leeds holds a doctorate. in Medical Microbiology and Immunology from the University of Wisconsin-Madison and a BS in Microbiology from Cornell University. She completed her postdoctoral fellowship at Harvard Medical School with Jon Beckwith, assessing the genetic and biophysical characterization of the structure and function of integral membrane proteins.

“As a long-time drug discoverer and leader in the pharmaceutical industry with a current professional focus on business development, I am delighted to be working with 1910 Genetics as an independent member of the board of directors to assist the company and its investors to achieve their key scientific and business goals, ”said Dr Leeds.

Around 1910 Genetics

1910 Genetics integrates AI, computation and biological automation to accelerate the design of small molecule and protein therapies. The company combines AI-based drug design with the automation of biological wet labs to increase productivity and reduce failure rates throughout the pharmaceutical R&D process. Using its multiplatform drug discovery engines – ELVIS â„¢ and ROSALYND â„¢ – 1910 Genetics can generate more new drug candidates, shorten lead times, reduce operational costs and increase the chances of success over traditional pharmaceutical methods. 1910 Genetics’ end-to-end, therapeutically independent technology powers the entire lifespan of early drug discovery – from finding new successes to optimizing leads. 1910 Genetics is currently applying its technology to drug discovery programs in several fields, including, but not limited to, neuroscience, oncology, immunology, and infectious diseases. The company was founded in 2018 and is headquartered in Boston, Massachusetts. To learn more about 1910 Genetics, visit www.1910genetics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211215005296/en/

CONTACT: Michelle Linn

Bioscribe, Inc.

[email protected]



SOURCE: 1910 Genetics

Copyright Business Wire 2021.

PUB: 12/15/2021 08: 00 / DISC: 12/15/2021 08:01


Copyright Business Wire 2021.


About Author

Comments are closed.